Susan Haigney

5 days ago | biopharminternational.com | Susan Haigney

The European Medicines Agency (EMA) announced on June 20, 2025 that it has recommended that Zemcelpro (dorocubicel/unexpanded umbilical cord cells) be granted conditional marketing authorization for the treatment of adults with hematological malignancies (blood cell cancers). Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available.

1 week ago | biopharminternational.com | Susan Haigney |Patrick Lavery

In BioPharm International®’s continuing conversation with Ram Aiyar, PhD, of Korro Bio, the company’s CEO and president discusses the work Korro has been doing on RNA editing for a wide range of targets, and how that research and knowledge can be brought to a wider audience of potential patients with the assistance of a major player in the biopharmaceutical industry. “That's where pharma companies really come into the picture, where it's like they are more interested.

1 week ago | biopharminternational.com | Susan Haigney |Patrick Lavery

As the Biotechnology Innovation Organization (BIO) International Convention meets in Boston from June 16–19, 2025, BioPharm International® caught up with Ram Aiyar, PhD, CEO and president of Cambridge, Mass.-based Korro Bio. In the interview, Aiyar explains the broader implications of Korro’s OPERA platform, short for “Oligonucleotide Promoted Editing of RNA.” Increased precision, he said, is the key to addressing a broader range of diseases.

1 week ago | biopharminternational.com | Susan Haigney

Ecolab Life Sciences is launching its new Purolite AP+50 affinity chromatography resin at the Biotechnology Innovation Organization (BIO) International Convention, which is being held in Boston from June 16–19, 2025. The new resin, according to a June 16, 2025 press release (1), can optimize operations during the antibody manufacturing process.

1 week ago | biopharminternational.com | Susan Haigney

Developing a biopharmaceutical includes multiple steps and a variety of factors that must be taken into consideration. While commercial manufacturing and tech transfer may seem far downstream in the process from development, they are actually important parts of the formulation process. “A great example is with the selection of raw materials and alignment with global compendia,” explains Robert Cornog, senior director, Product Development, at Quotient Sciences.